Novartis is temporarily suspending production of Lutathera and Pluvicto over “potential quality issues identified in its manufacturing processes,” it said May 5.
Read the full post on Becker's Hospital Review - Healthcare News
Novartis suspends production of 2 cancer treatments over quality concerns
